Time to Diagnosis of Neuroendocrine Tumors (NETs): Results from the First Global NET Patient (pt) Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
#1220
Introduction: Diagnosis of NETs often occurs late in the disease course, which may have an impact on pt survival. We present pt-reported data on time to diagnosis in global NET pts.
Aim(s): To raise awareness of the NET pt perspective and challenges faced while seeking a diagnosis.
Materials and methods: Anonymous survey of 1928 NET pts from >12 countries conducted by INCA Novartis in 2014 (Americas, Asia, Europe, Oceania) on the NET pt experience, including diagnosis. This NET patient survey was a collaboration between INCA and Novartis and the survey was funded by Novartis.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Pavel M, Goldstein G, Sissons M, Kolarova T, Leyden J,
Keywords: Diagnosis,
To read the full abstract, please log into your ENETS Member account.